First Phase I trials of in vivo antisense product (ISIS 2105) will begin during the week of March 23. The product is being developed for the treatment of genital warts. Five dosing levels will be used to evaluate the safety of ISIS 2105, with ten volunteers receiving each dose level. The company plans to enter Phase II studies within the year, though it has not yet submitted a protocol.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth